MiMedx Group (MDXG) Expected to Announce Earnings on Wednesday

MiMedx Group (NASDAQ:MDXG) will likely be releasing its Q1 2026 results after the market closes on Wednesday, April 29th. Analysts expect MiMedx Group to post earnings of ($0.03) per share and revenue of $69.4670 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 4:30 PM ET.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%.The business had revenue of $118.10 million for the quarter, compared to analysts’ expectations of $106.78 million. On average, analysts expect MiMedx Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiMedx Group Price Performance

MDXG stock opened at $3.43 on Monday. MiMedx Group has a 52-week low of $3.18 and a 52-week high of $7.99. The stock’s fifty day simple moving average is $4.27 and its 200-day simple moving average is $5.71. The company has a quick ratio of 3.92, a current ratio of 4.32 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $509.60 million, a price-to-earnings ratio of 10.72 and a beta of 1.65.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on MDXG. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a report on Monday, December 29th. UBS Group set a $10.00 target price on MiMedx Group in a research report on Monday, February 23rd. Wall Street Zen lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Cantor Fitzgerald cut their target price on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 17th. Finally, Craig Hallum cut their target price on MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, MiMedx Group has an average rating of “Moderate Buy” and an average target price of $8.67.

Hedge Funds Weigh In On MiMedx Group

Several hedge funds and other institutional investors have recently made changes to their positions in the business. SkyView Investment Advisors LLC boosted its position in shares of MiMedx Group by 3.6% during the second quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after buying an additional 3,032 shares during the period. Rafferty Asset Management LLC boosted its position in shares of MiMedx Group by 4.6% during the fourth quarter. Rafferty Asset Management LLC now owns 69,304 shares of the company’s stock worth $469,000 after buying an additional 3,064 shares during the period. Aviva PLC boosted its position in shares of MiMedx Group by 4.7% during the fourth quarter. Aviva PLC now owns 71,234 shares of the company’s stock worth $482,000 after buying an additional 3,211 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of MiMedx Group by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after buying an additional 4,049 shares during the period. Finally, AQR Capital Management LLC boosted its position in shares of MiMedx Group by 42.6% during the first quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after buying an additional 4,296 shares during the period. 79.15% of the stock is currently owned by institutional investors and hedge funds.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.